JP2013507954A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507954A5
JP2013507954A5 JP2012535105A JP2012535105A JP2013507954A5 JP 2013507954 A5 JP2013507954 A5 JP 2013507954A5 JP 2012535105 A JP2012535105 A JP 2012535105A JP 2012535105 A JP2012535105 A JP 2012535105A JP 2013507954 A5 JP2013507954 A5 JP 2013507954A5
Authority
JP
Japan
Prior art keywords
cancer cells
pharmaceutical composition
peptides
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012535105A
Other languages
English (en)
Other versions
JP5751519B2 (ja
JP2013507954A (ja
Filing date
Publication date
Priority claimed from KR1020090101003A external-priority patent/KR101061017B1/ko
Application filed filed Critical
Publication of JP2013507954A publication Critical patent/JP2013507954A/ja
Publication of JP2013507954A5 publication Critical patent/JP2013507954A5/ja
Application granted granted Critical
Publication of JP5751519B2 publication Critical patent/JP5751519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (4)

  1. 有効成分としての配列番号１１〜１４のペプチドからなる群から選択されるペプチド、及び薬学的に許容可能な担体を含む炎症疾患の予防用または治療用の薬学組成物。
  2. 前記炎症性疾患が、急性接触性皮膚炎、アレルギー性炎症またはリューマチ性関節炎であることを特徴とする請求項１に記載の薬学組成物。
  3. 有効成分としての配列番号１１〜１４のペプチドからなる群から選択されるペプチド、及び薬学的に許容可能な担体を含むガン細胞の成長抑制用及び／または転移抑制用の薬学組成物。
  4. 前記ガン細胞が、乳ガン細胞、胃ガン細胞、大腸ガン細胞、結腸ガン細胞、直腸ガン細胞、膵臓ガン細胞またはリンパ腫細胞であることを特徴とする請求項３に記載の薬学組成物。
JP2012535105A 2009-10-23 2010-08-24 白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質 Active JP5751519B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020090101003A KR101061017B1 (ko) 2009-10-23 2009-10-23 암세포의 성장 및/또는 전이 억제용 약학 조성물
KR10-2009-0101003 2009-10-23
PCT/KR2010/005619 WO2011049289A2 (ko) 2009-10-23 2010-08-24 백혈구의 혈관외유출 또는 암세포의 성장 및/또는 전이를 억제하는 폴리펩타이드 또는 그의 융합 단백질

Publications (3)

Publication Number Publication Date
JP2013507954A JP2013507954A (ja) 2013-03-07
JP2013507954A5 true JP2013507954A5 (ja) 2014-08-07
JP5751519B2 JP5751519B2 (ja) 2015-07-22

Family

ID=43900764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535105A Active JP5751519B2 (ja) 2009-10-23 2010-08-24 白血球の血管外遊出またはガン細胞の成長及び／もしくは転移を抑制するポリペプチドまたはその融合蛋白質

Country Status (6)

Country Link
US (1) US8530421B2 (ja)
EP (2) EP2491944A4 (ja)
JP (1) JP5751519B2 (ja)
KR (1) KR101061017B1 (ja)
CN (1) CN102711792A (ja)
WO (1) WO2011049289A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101644982B1 (ko) * 2015-07-23 2016-08-02 주식회사 엔솔바이오사이언스 신규 펩타이드 및 그 용도
AU2017227790B2 (en) * 2016-03-02 2023-03-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Matrix bound nanovesicles and their use
US20200095296A1 (en) * 2017-06-05 2020-03-26 The Trustees Of Columbia University In The City Of New York Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and tcr and/or hla immunoprofiling in neurodegenerative disease
KR102268921B1 (ko) * 2019-12-10 2021-06-23 강원대학교산학협력단 p53을 활성화하는 펩타이드를 포함하는 조성물
KR20210074207A (ko) * 2019-12-11 2021-06-21 강원대학교산학협력단 p53과 FOXO4의 상호작용을 억제시키는 펩타이드를 포함하는 약학 조성물
KR20230033097A (ko) * 2021-08-27 2023-03-08 (주)티카로스 기능이 강화된 신규 키메라 항원 수용체(car)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
CA2305681C (en) * 1997-09-30 2013-01-08 Peviva Ab Apoptosis-related compounds and their use
EP1133317A1 (de) * 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
US6451969B1 (en) * 1999-01-15 2002-09-17 The Burnham Institute Methods for inhibiting tumor metastasis, and peptides useful therfor
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
ES2368419T3 (es) * 2000-03-13 2011-11-17 Cornell Research Foundation, Inc. Bloqueo de la migración de leucocitos y de la inflamación por interferencia con cd99/hec2.
CH694935A5 (de) * 2000-07-26 2005-09-30 Straumann Holding Ag Oberflaechenmodifizierte Implantate.
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
MXPA05001873A (es) * 2002-08-21 2005-06-03 Merck Patent Gmbh Epitopes de celula t en enterotoxina b estafilococica.
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
WO2005074986A2 (en) * 2004-02-10 2005-08-18 Genobiotix Aps Bioactive species capable of interfering with a microbial toxin-antitoxin complex and methods for evaluation and use of said bioactive species
WO2007005898A2 (en) 2005-07-05 2007-01-11 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99l2
WO2007037601A1 (en) * 2005-09-28 2007-04-05 Knu-Industry Cooperation Foundation Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof
KR100793947B1 (ko) * 2006-06-30 2008-01-16 강원대학교산학협력단 암세포의 성장 및 전이 억제 활성을 갖는 폴리펩타이드또는 그의 융합 단백질
KR100793949B1 (ko) * 2006-07-19 2008-01-16 강원대학교산학협력단 염증 질환의 예방 또는 치료 활성을 갖는 폴리펩타이드또는 그의 융합 단백질
KR100941678B1 (ko) 2007-12-17 2010-02-12 강원대학교산학협력단 암세포의 전이 억제 활성을 갖는 폴리펩타이드 또는 그의융합 단백질
KR101074005B1 (ko) * 2009-02-26 2011-10-17 재단법인춘천바이오산업진흥원 백혈구의 혈관외유출 억제 활성을 갖는 폴리펩타이드 또는 그의 융합 단백질

Similar Documents

Publication Publication Date Title
JP2013507954A5 (ja)
WO2017044894A3 (en) Cartilage-homing peptides
EA201400172A1 (ru) Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
TR201903195T4 (tr) Apiksaban formülasyonları.
CL2013003331A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz.
JP2009286795A5 (ja)
WO2013066839A3 (en) Compounds and methods
MX2013000821A (es) Nuevas aminopirazoloquinazolinas.
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
NI201100155A (es) Composiciones y métodos para el tratamiento prolongado con aminopiridinas
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2014501492A5 (ja)
JP2018048151A5 (ja)
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
JP2014529399A5 (ja)
EP2560642A4 (en) TREATMENT OF GICHT
MX2016005003A (es) Marcadores geneticos predictivos de respuesta al acetato de glatiramero.
TN2012000046A1 (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorfers
MX340626B (es) Levoisovalerilespiramicina i, ii, iii y preparaciones, métodos de preparación y sus usos.
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
NZ596313A (en) Pharmaceutical compositions containing antifungal peptides
JP2016510596A5 (ja)
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
NZ629964A (en) Method for treating inflammation
JP2013542196A5 (ja)